Related Experiment Video
Updated: Jul 2, 2025
Combination of High Ligation and Intraoperative Embolization using Polidocanol for Treatment of Varicoceles
Published on: December 22, 2023
A Retrospective Follow-Up Study To Show The Effectiveness Of Booster Dose Of Foam Sclerotherapy Session At 3rd And
Farid Ullah Khan1, Nauman Imtiaz2, Irfan Khan2
1Department of Pharmacology, Avicenna Medical College Lahore, Pakistan.
Insights
Booster doses of injection sclerotherapy at 3rd and 6th months significantly reduced varicose vein disease recurrence by 50%. This outpatient procedure offers an effective treatment option for low-risk patients.
Area of Science:
- Vascular Surgery
- Dermatology
- Phlebology
Background:
- Injection sclerotherapy is a recognized treatment for varicose vein disease.
- Varicose vein recurrence remains a clinical challenge.
- The study investigates the impact of booster doses on recurrence rates.
Purpose of the Study:
- To evaluate the efficacy of booster doses of injection sclerotherapy in reducing varicose vein recurrence.
- To assess the recurrence rates at 3 and 6 months post-initial treatment with booster sessions.
Main Methods:
- A cohort of 150 low-risk patients (ages 30-70) participated.
- Exclusion criteria included high-risk comorbidities, allergies, and specific vascular conditions.
- Booster Foam Sclerotherapy sessions were administered at 3 and 6 months, with outcomes documented.
Main Results:
- A 50% decrease in varicose vein recurrence was observed with booster injections.
- The procedure was conducted in an outpatient setting, requiring no specialized anesthesia.
- Booster doses at 3 and 6 months proved effective in managing recurrence.
Conclusions:
- Booster doses of injection sclerotherapy are effective in decreasing varicose vein recurrence.
- This treatment modality is suitable for outpatient management of low-risk patients.
- Further research may explore long-term efficacy and optimal timing of booster sessions.
Background:
Injection sclerotherapy administration is known to cause a decreased recurrence of varicose vein disease. This research aimed to investigate the recurrence of varicose vein disease after giving booster doses of injection sclerotherapy. The booster doses were given at 3rd and 6th months.
Methods:
One hundred and fifty patients participated and all patient's included ages 30-70 in the category of 'low risk' patients. The patients were both males and females. Patients participating in the study were counselled appropriately and written consent was taken from them. Moreover, the patients selected were volunteers and agreed to be part of the study. Patients who were above 70 years of age, those who were at a high-risk due to some co-morbidities (high-risk patients), patients not willing to be part of the study, those allergic to drugs being used including sclerosant and people with any known psychiatric illness or cardiac arrhythmias, deep venous thrombosis patients, patients having arteriovenous malformation/venous ulcers were all excluded. If the patient was pregnant, the gynaecology team was taken on board and the procedure was carried out. Every procedure was carried out under the direct supervision of the supervisor. Booster dose sessions of Foam Sclerotherapy were held at 3rd and 6th months of the study time. Their effectiveness was observed and documentation was carried out.
Results:
Since it was a procedure that could be done in the OPD, there was no need for specialized anaesthesia care. It is of significant notice that when a patient of varicose veins was given a booster intravenous sclerosant injection at 3rd and 6th month of treatment, chances of recurrence decreased to 50%.
